

1763369 PCT/08A (10-96)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

**Complete if Known**

Application Number	
Filing Date	even date herewith
First Named Inventor	ZAGURY et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	ZAGURY3A

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA					

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
	AB	EP	0 330 359	A2	BIO-RAD LABORATORIES, INC.	08-30-1989		
	AC							

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AD	ZAGURY et al., "Antibodies to the HIV-1 Tat Protein Correlated With Nonprogression to AIDS: A Rationale for the Use of Tat Toxoid as an HIV-1 Vaccine," J. of Human Virology, May/June 1998, Vol. 1, No. 4, pp. 282-292.	
	AE	RODMAN et al., "Epitopes for Natural Antibodies of Human Immunodeficiency Virus (HIV)-negative(normal) and HIV-positive sera are coincident with two key functional sequences of HIV tat Protein," Proc. of Nat. Academy of Sciences, USA, August 1993, Vol. 90, pp. 7719-7723.	
	AF	RODMAN et al., "Natural Antibodies. Early host defense against HIV?," International Conf. on AIDS, 1992, Vol. 8, No. 2, page A74 (abstract No. POA 2429).	
	AG	RE et al., "Antibody Against Human Immunodeficiency Virus type 1 (HIV-1). Tat Protein may have influenced the progression of AIDS in HIV-1 infected hemophilic patients," Clinical and Diagnostic Laboratory Immunology, March 1996, Vol. 3, No. 2, pp. 230-232.	
	AH	RE et al., "Effect of Antibody to HIV-1 Tat Protein on Viral replication in vitro and progression of HIV-1 disease in vivo," J. of Acquired Immune Deficiency Syndromes and Human Retrovirology. December 1, 1995, Vol. 10, No. 4, pp. 408-416.	
	AI	RODMAN et al., "Human Immunodeficiency virus (HIV) Tat reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope," J. of Experimental Medicine. 1 May 1992, Vol. 175, No. 5, pp. 1247-1253.	

Examiner  
SignatureDate  
Considered

06/22/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

#7

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number 09/763,369  
 Filing Date May 22, 2001  
 First Named Inventor ZAGURY et al.  
 Group Art Unit  
 Examiner Name  
 Attorney Docket Number ZAGURY3A

**RECEIVED**

MAY 01 2003

TECH CENTER 1600/2909

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
J	AJ	5,108,891		CROXSON	04-28-1992	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number	Kind Code <sup>5</sup> (if known)				
J	AK	DE	195 14 089 A1		DEUTSCHES KREBSFORSCH	10-24-1996		Yes

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
J	AL	GRINGERI et al., Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients, <u>Journal of Human Virology</u> , 1:293-298 (1998)	
	AM	REISS et al., Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals, <u>Journal of Acquired Immune Deficiency Syndromes</u> , 4:165-172 (1991)	
	AN	GIBELLINI et al., Antibody to HIV-1 tat protein, a key molecule in HIV-1 pathogenesis. A brief review, <u>Microbiologica</u> , 24:197-205 (20010)	

Examiner  
SignatureDate  
Considered

06/22/03

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.